HAVCR2 and neoplasm: On the other hand, great progress has achieved in discovering novel immune checkpoints which could also synergize with PD-1/PD-L1 and were non-redundant in restricting the anti-tumor response of immune cells, such as TIGIT, LAG-3, TIM-3 and CD47 [5].